ALHC

AI Memo

Alignment Healthcare

As of 2026-10-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

2027 Medicare Advantage Star Ratings • 2026-10-31

Base target: $8 / p=45% prob

Biggest risk

A weaker Star Rating, higher utilization, or costly new-market enrollment could offset growth. The announced expansion establishes access, not profitable membership. Company Q2 release Company 2027 portfolio announcement

Invalidation

Break below $5 or thesis failure.

What would change my mind?

Q2 membership rose 31.5% year over year, adjusted gross profit rose 35.3%, and the adjusted medical benefits ratio improved about 40 basis points. Successful 2027 enrollment without claims-cost deterioration could extend operating leverage. [#IR-Q2-2026-07-30] Company Q2 release

Research note

Recommendation

—

Confidence

medium

As of

2026-10-02

Base target

p=45%

Bull target

$13

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 membership rose 31.5% year over year, adjusted gross profit rose 35.3%, and the adjusted medical benefits ratio improved about 40 basis points.
Successful 2027 enrollment without claims-cost deterioration could extend operating leverage.
[#IR-Q2-2026-07-30] Company Q2 release

BearKey bullets

Medical-cost pressure could prevent delivery of Q3 adjusted gross profit and EBITDA guidance.
[#IR-Q2-2026-07-30] Company Q2 release
New-county and provider-network expansion may add members without producing expected margins.

WatchKey bullets

2027 Medicare Advantage Star Ratings

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $8 (p=45%)

Target spread vs base: +49% / -43%

Scenario probabilities

Bull Target: $13 (p=25%)Base Target: $8 (p=45%)Bear Target: $5 (p=30%)

Commentary

The October 1 $7.74 anchor is substantially below the $13.68 price cited in a September 4 secondary article, but that comparison does not establish the cause of the decline. The October 1 company expansion announcement adds a concrete forward hook; enrollment and margin results remain unproven. Verified post-selloff analyst revisions and dependable social, options, short-interest and employee measures are unavailable; zero sentiment fields mean missing data, not neutral readings.

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 membership rose 31.5% year over year, adjusted gross profit rose 35.3%, and the adjusted medical benefits ratio improved about 40 basis points.
Successful 2027 enrollment without claims-cost deterioration could extend operating leverage.
[#IR-Q2-2026-07-30] Company Q2 release

Scenarios

Bull Target (Scenario probability)

$13 / p=25% prob

Base Target (Scenario probability)

$8 / p=45% prob

Bear Target (Scenario probability)

$5 / p=30% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.40

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-31
2027 Medicare Advantage Star Ratings
The forthcoming ratings could change the outlook for future quality-bonus economics. Alignment identifies maintaining high plan ratings as a material risk; a downgrade is not confirmed. [#8-K-2026-07-30] Company Q2 release CMS ratings policy
Prob 50.00% • Move 20.00% • Priced-in 55.00%
EVENT2026-11-15
Q3 results test medical-cost control
After Q2 revenue of $1.336 billion and approximately 294,100 members, company Q3 guidance calls for $1.30–$1.32 billion of revenue and $20–$30 million of adjusted EBITDA. Delivery against those ranges is the next operating test; the result date is an estimate, not a company-announced date. [#8-K-2026-07-30] [#IR-Q2-2026-07-30] Company Q2 release
Prob 55.00% • Move 18.00% • Priced-in 40.00%
EVENT2027-01-01
Enrollment test for the expanded 2027 plan portfolio
Alignment announced 77 plans across 55 counties for 2027, including 10 new counties, with annual enrollment running October 15–December 7. The opportunity is disclosed, but enrollment and medical-cost outcomes are not yet known. [#IR-2026-10-01] Company announcement
Prob 55.00% • Move 15.00% • Priced-in 35.00%

Risks

Medical-cost pressure could prevent delivery of Q3 adjusted gross profit and EBITDA guidance. [#IR-Q2-2026-07-30] Company Q2 release
New-county and provider-network expansion may add members without producing expected margins. Company 2027 portfolio announcement
Packet Form 4 records show September executive sales, but sales alone do not establish operating deterioration. [#SEC-FORM4-2026-09-11] [#SEC-FORM4-2026-09-16] [#SEC-FORM4-2026-09-18]
September shareholder-law-firm investigations are allegations, not findings; the packet does not establish their merits.
Star-Rating deterioration could weaken future quality-bonus economics; no downgrade is established. Company Q2 release

Peers

Symbol	Summary
ASTH	A value-based care provider rather than a direct insurer peer. Alignment announced Astrana as a 2027 Southern California network addition; no economic exposure was disclosed. Company announcement
CLOV	A more relevant Medicare Advantage comparison than medical-device names, though scale, geography and plan economics limit direct valuation comparisons.
HUM	A large Medicare Advantage benchmark for utilization and ratings sensitivity, not a close size or margin comparable.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

ASTH

A value-based care provider rather than a direct insurer peer. Alignment announced Astrana as a 2027 Southern California network addition; no economic exposure was disclosed. Company announcement

CLOV

A more relevant Medicare Advantage comparison than medical-device names, though scale, geography and plan economics limit direct valuation comparisons.

HUM

A large Medicare Advantage benchmark for utilization and ratings sensitivity, not a close size or margin comparable.